Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

alk-abelló ag - canis pilorum allergeni extractum (canis lupus familiaris) - pricktestlösung - canis pilorum allergeni extractum (canis lupus familiaris) 10 u., natrii chloridum, phenolum, glycerolum, dinatrii phosphas dihydricus, natrii dihydrogenophosphas dihydricus, natrii hydroxidum ad ph, acidum hydrochloridum ad ph, aqua ad iniectabile ad solutionem pro 1 ml, u = histamin equivalent prick. - diagnostic des allergies de soforttyps - allergène: diagnostic

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

allergopharma ag - canis pellis allergeni extractum (canis lupus familiaris) - pulver und lösungsmittel zur herstellung einer provokationstestlösung - praeparatio cryodesiccata: canis pellis allergeni extractum (canis lupus familiaris) 25000 u., mannitolum, pro vitro. solvens: natrii chloridum, natrii hydrogenocarbonas, phenolum, aqua q.s. ad solutionem pro 1 ml. - diagnostic de l'allergie - allergène: diagnostic

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

allergopharma ag - canis pellis allergeni extractum (canis lupus familiaris) - pricktestlösung - canis pellis allergeni extractum (canis lupus familiaris) 10000 u., natrii chloridum, glycerolum, phenolum, aqua ad iniectabile ad solutionem pro 1 ml. - diagnostic de l'allergie - allergène: diagnostic

Union européenne - français - EMA (European Medicines Agency)

sanofi winthrop industrie - sarilumab - arthrite, rhumatoïde - immunosuppresseurs - kevzara en association avec le méthotrexate (mtx) est indiqué pour le traitement de modérément à sévèrement active polyarthrite rhumatoïde (pr) chez les patients adultes qui ont mal répondu à, ou qui ont une intolérance à un ou plusieurs maladie anti rhumatismale médicaments (armm). kevzara peut être administré en monothérapie en cas d'intolérance au mtx ou lorsque le traitement par mtx est inapproprié.

Union européenne - français - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - agents contre la dermatite, à l'exclusion des corticostéroïdes - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Canada - français - Health Canada

sanofi-aventis canada inc - sarilumab - solution - 150mg - sarilumab 150mg - disease-modifying antirheumatic agents

Canada - français - Health Canada

sanofi-aventis canada inc - sarilumab - solution - 200mg - sarilumab 200mg - disease-modifying antirheumatic agents

Canada - français - Health Canada

sanofi-aventis canada inc - dupilumab - solution - 300mg - dupilumab 300mg - misc. skin and mucous membrane agents

Canada - français - Health Canada

sanofi-aventis canada inc - sarilumab - solution - 150mg - sarilumab 150mg - disease-modifying antirheumatic agents

Canada - français - Health Canada

sanofi-aventis canada inc - sarilumab - solution - 200mg - sarilumab 200mg - disease-modifying antirheumatic agents